Perrigo Company plc (NYSE:PRGO – Get Free Report) announced a quarterly dividend on Thursday, July 30th. Stockholders of record on Friday, August 28th will be paid a dividend of 0.29 per share on Tuesday, September 15th. This represents a c) annualized dividend and a dividend yield of 11.2%. The ex-dividend date is Friday, August 28th.
Perrigo has raised its dividend by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 23 years. Perrigo has a dividend payout ratio of 35.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Perrigo to earn $2.40 per share next year, which means the company should continue to be able to cover its $1.16 annual dividend with an expected future payout ratio of 48.3%.
Perrigo Stock Down 0.6%
Shares of NYSE:PRGO opened at $10.36 on Friday. The firm has a 50 day simple moving average of $10.55 and a 200-day simple moving average of $11.65. Perrigo has a twelve month low of $9.23 and a twelve month high of $27.33. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The company has a market capitalization of $1.43 billion, a PE ratio of -0.79, a P/E/G ratio of 1.24 and a beta of 0.51.
Analysts Set New Price Targets
Several analysts have recently weighed in on PRGO shares. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Perrigo presently has an average rating of “Hold” and a consensus target price of $19.33.
Read Our Latest Analysis on Perrigo
About Perrigo
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Further Reading
- Five stocks we like better than Perrigo
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
